5/15/2024 | SPSW | Structured products issuance $947 million for week; $401 million Eli Lilly deal eyed
|
3/13/2024 | SPSW | Structured notes tally for week $494 million; stocks, ETFs strong amid low volatility
|
2/28/2024 | SPSW | Weekly structured notes tally $292 million amid Nvidia-induced stock market mania
|
2/21/2024 | SPSW | Structured products tally $541 million for week; big $305 million Regeneron-linked deal eyed
|
2/16/2024 | CVSP | New Issue: Morgan Stanley sells $275 million cash-settled equity-linked notes on Regeneron
|
1/5/2024 | BKIG | Moody’s boosts Regeneron
|
6/28/2023 | SP | New Issue: JPMorgan prices $1.58 million return notes linked to basket of 20 stocks
|
2/23/2023 | BKIG | Moody's upgrades Regeneron
|
12/20/2022 | BK | Regeneron enters replacement $750 million five-year revolver
|
7/5/2022 | BKIG | Moody's views Regeneron positively
|
3/26/2021 | SP | New Issue: JPMorgan prices $525,000 callable contingent interest notes on Regeneron
|
3/23/2021 | SP | New Issue: JPMorgan prices $3.42 million callable contingent interest notes on Regeneron
|
1/26/2021 | SP | New Issue: UBS prices $100,000 buffered return optimization securities linked to Regeneron
|
12/29/2020 | SP | New Issue: GS Finance sells $1.71 million leveraged basket-linked notes on 23 stocks
|
12/19/2020 | SP | New Issue: Credit Suisse prices $2.8 million Accelerated Return Equity Securities on stock basket
|
12/19/2020 | SP | New Issue: Credit Suisse prices $1.43 million Accelerated Return Equity Securities on stock basket
|
11/19/2020 | SP | New Issue: BofA prices $1.17 million contingent income buffered autocalls on stocks
|
9/2/2020 | SP | New Issue: Goldman prices $1.2 million leveraged basket-linked notes on 20 stocks
|
8/7/2020 | EMHYPFPV | Market Commentary: Regeneron sells $2 billion notes; steady supply expected; fund, ETF inflows rise
|
8/7/2020 | IG | Market Commentary: Regeneron sells $2 billion notes; steady supply expected; fund, ETF inflows rise
|
8/7/2020 | IG | New Issue: Regeneron Pharmaceuticals prices $2 billion of senior notes in two tranches
|
8/7/2020 | IG | Market Commentary: Morning Commentary: Regeneron offers two tranches; bond fund, ETF inflows rise
|
8/7/2020 | BKIG | Moody’s rates Regeneron notes Baa3
|
8/7/2020 | IG | Regeneron to conduct sale of fixed-rate senior notes in two tranches
|
8/7/2020 | BKIG | S&P rates Regeneron notes BBB+
|
8/5/2020 | BKIG | S&P gives Regeneron BBB+
|
8/5/2020 | BKIG | Moody’s assigns Baa3 to Regeneron
|
4/24/2020 | SP | New Issue: Goldman prices $1.73 million leveraged basket-linked notes on 19 stocks
|
4/12/2020 | SP | New Issue: JPMorgan prices $1 million digital contingent buffered notes on Regeneron
|
2/3/2020 | SP | New Issue: Credit Suisse sells $1.21 million contingent coupon autocallable reverse convertibles on three stocks
|
11/20/2019 | SP | New Issue: UBS prices $745,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
10/18/2019 | SP | New Issue: UBS prices $100,000 buffered return optimization securities linked to Regeneron Pharmaceuticals
|
5/24/2019 | SP | New Issue: Credit Suisse sells $3.59 million contingent coupon autocallable reverse convertibles on Regeneron
|
5/16/2019 | SP | New Issue: UBS prices $600,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
4/17/2019 | SP | New Issue: UBS prices $176,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
3/6/2019 | SP | New Issue: Citigroup sells $500,000 autocallable equity-linked notes on four stocks
|
2/14/2019 | SP | Citigroup plans autocallable equity-linked notes tied to four stocks
|
12/17/2018 | BK | Regeneron gets $750 million five-year revolver at Libor plus 125 bps
|
10/31/2018 | SP | New Issue: UBS prices $275,000 trigger phoenix autocallables linked to Regeneron
|
9/25/2018 | SP | New Issue: UBS prices $136,000 trigger phoenix autocallables linked to Regeneron
|
7/10/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Regeneron
|
4/9/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Regeneron
|
4/6/2018 | SP | New Issue: Credit Suisse sells $1.58 million contingent 10.75% autocall reverse converts on Regeneron
|
3/28/2018 | SP | New Issue: Credit Suisse sells $1.53 million contingent coupon autocallable reverse convertibles on Regeneron
|
3/12/2018 | SP | New Issue: UBS prices $250,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
2/9/2018 | SP | New Issue: Citigroup sells $572,000 autocallable equity-linked notes tied to pharma stocks
|
1/23/2018 | SP | New Issue: UBS prices $110,000 trigger phoenix autocallables linked to Regeneron
|
1/9/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Regeneron
|
1/4/2018 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallables linked to Regeneron
|
12/20/2017 | SP | New Issue: UBS prices $133,000 trigger phoenix autocallables linked to Regeneron
|
12/15/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
12/11/2017 | SP | New Issue: UBS prices $395,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
12/6/2017 | SP | New Issue: UBS prices $100,000 trigger autocallables linked to Regeneron
|
9/27/2017 | SP | New Issue: Credit Suisse prices $500,000 10% autocallable reverse convertibles linked to pharma stocks
|
9/1/2017 | SP | New Issue: UBS prices $455,000 trigger phoenix autocallables linked to Regeneron
|
7/14/2017 | SP | New Issue: UBS prices $940,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
7/14/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
5/26/2017 | SP | New Issue: UBS prices $350,000 trigger phoenix autocallables linked to Regeneron
|
5/23/2017 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallables linked to Regeneron
|
5/12/2017 | SP | New Issue: UBS prices $560,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
5/2/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Regeneron
|
4/18/2017 | SP | New Issue: Credit Suisse sells $679,000 autocallable yield notes on pharma stocks
|
4/5/2017 | SP | New Issue: UBS prices $335,000 trigger phoenix autocallables linked to Regeneron
|
3/13/2017 | SP | New Issue: UBS prices $810,000 trigger phoenix autocallables linked to Regeneron
|
3/1/2017 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallables linked to Regeneron
|
2/15/2017 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallables linked to Regeneron
|
1/4/2017 | SP | New Issue: UBS prices $300,000 trigger phoenix autocallables linked to Regeneron
|
1/3/2017 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
1/3/2017 | SP | New Issue: UBS prices $205,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
12/7/2016 | SP | New Issue: UBS prices $275,000 trigger phoenix autocallables linked to Regeneron
|
12/6/2016 | SP | New Issue: UBS prices $150,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
11/28/2016 | SP | New Issue: UBS prices $570,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
11/4/2016 | SP | New Issue: UBS prices $125,000 trigger phoenix autocallables linked to Regeneron
|
10/11/2016 | SP | New Issue: Barclays prices $3.23 million autocallable notes tied to Regeneron
|
9/28/2016 | SP | Barclays plans to price autocallable securities linked to Regeneron
|
9/20/2016 | SP | New Issue: Barclays sells $3.44 million of phoenix autocallables tied to Regeneron
|
9/16/2016 | SP | New Issue: HSBC prices $3 million of AMPS linked to basket of 20 common stocks
|
9/13/2016 | SP | Barclays plans to price phoenix autocallable notes tied to Regeneron
|
9/8/2016 | SP | HSBC plans 15-month AMPS with cap linked to basket of 20 stocks
|
8/22/2016 | CV | Market Commentary: Morning Commentary: Convertibles quiet with summer slowdown in full swing; Illumina inactive
|
7/19/2016 | SP | New Issue: HSBC prices $1.54 million contingent income autocallables linked to Regeneron
|
7/7/2016 | SP | HSBC plans contingent income autocallables linked to Regeneron
|
6/14/2016 | SP | New Issue: Citigroup prices $2.14 million contingent coupon autocallables linked to Regeneron
|
6/13/2016 | SP | New Issue: RBC prices $1.75 million contingent income autocallables linked to Regeneron
|
6/1/2016 | SP | RBC plans contingent income autocallables due 2016 linked to Regeneron
|
5/23/2016 | SP | New Issue: Credit Suisse prices $1.82 million contingent coupon autocallables on pharma stocks
|
5/18/2016 | SP | Credit Suisse plans contingent coupon autocallable yield notes linked to three stocks
|
3/24/2016 | SP | New Issue: Wells Fargo prices $5.23 million of 0.125% notes tied to pharma stocks
|
3/22/2016 | SP | Wells Fargo to price 0.125% notes linked to four pharma stocks
|
1/14/2016 | SP | New Issue: JPMorgan prices $8.8 million autocallable reverse exchangeables linked to pharma stocks
|
1/13/2016 | SP | New Issue: Barclays prices $981,000 contingent income autocallables on Regeneron
|
1/7/2016 | SP | Barclays plans contingent income autocallables linked to Regeneron
|
1/6/2016 | SP | JPMorgan plans 10% autocallable reverse exchangeables linked to stocks
|
11/4/2015 | PP | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Tesla convertibles flat after earnings miss; Anthem adds on swap; FireEye contracts
|
11/4/2015 | CV | Market Commentary: Morning Commentary: Convertibles primary remains quiet; Tesla Motors adds after earnings miss
|
7/6/2015 | SP | New Issue: HSBC prices $3.05 million contingent income autocallables on Regeneron
|
6/19/2015 | SP | HSBC plans contingent income autocallable notes linked to Regeneron
|
6/11/2015 | SP | New Issue: JPMorgan prices $3.26 million capped return enhanced notes on S&P 500
|
5/20/2015 | SP | New Issue: CIBC prices $397,000 contingent coupon autocallables on Regeneron
|
3/30/2015 | SP | New Issue: JPMorgan prices $8 million 10% autocallable reverse exchangeables on three pharma stocks
|
3/23/2015 | BK | Regeneron gets $750 million five-year revolver at Libor plus 125 bps
|
3/5/2015 | CV | Market Commentary: NXP Semiconductors expands; Cheniere extends gains; Horizon Pharma deal looks ‘cheap’
|
12/30/2014 | SP | New Issue: Barclays prices $7.84 million autocallable notes linked to three pharmaceutical stocks
|
12/29/2014 | SP | Barclays plans autocallable notes tied to three pharmaceutical stocks
|
11/24/2014 | SP | New Issue: RBC prices $50,000 8.5% reverse convertibles linked to Regeneron Pharmaceuticals
|
11/12/2014 | SP | New Issue: UBS prices $232,000 airbag phoenix autocallables linked to Regeneron Pharmaceuticals
|
11/7/2014 | SP | RBC to price 8.5% reverse convertibles linked to Regeneron Pharmaceuticals
|
11/5/2014 | SP | UBS plans to price airbag phoenix autocallables linked to Regeneron
|
11/4/2014 | CV | Market Commentary: Slumping oil sends energy names lower; Cobalt, Goodrich down again; LinkedIn to price
|
11/4/2014 | CV | Market Commentary: Morning Commentary: Slumping oil sends energy names lower; Cobalt, Goodrich fall; Priceline down
|
10/30/2014 | SP | New Issue: RBC prices $27,000 8.35% reverse convertibles linked to Regeneron Pharmaceuticals
|
10/14/2014 | SP | RBC to price 7.15% reverse convertibles linked to Regeneron Pharmaceuticals
|
9/25/2014 | SP | New Issue: UBS prices $116,380 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
8/21/2014 | SP | RBC plans to price 8.75% reverse convertibles linked to Regeneron
|
8/20/2014 | SP | New Issue: RBC prices $80,000 9.25% reverse convertibles linked to Regeneron
|
8/8/2014 | SP | RBC to price 9.25% reverse convertibles linked to Regeneron
|
7/31/2014 | SP | New Issue: Morgan Stanley prices $2.36 million 7% airbag autocallables linked to Regeneron
|
7/30/2014 | SP | New Issue: RBC prices $597,000 9.5% reverse convertibles linked to Regeneron Pharmaceuticals
|
7/23/2014 | SP | Morgan Stanley plans 6%-7.25% airbag autocallables linked to Regeneron
|
7/22/2014 | SP | RBC to price 9.5% reverse convertibles linked to Regeneron Pharmaceuticals
|
7/22/2014 | SP | New Issue: UBS prices $208,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
6/23/2014 | SP | New Issue: UBS prices $666,500 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
5/29/2014 | SP | New Issue: Barclays prices $1 million 12.5% autocallable notes on three securities
|
5/15/2014 | SP | Barclays to price one-year autocallable notes linked to three stocks
|
4/23/2014 | SP | New Issue: UBS prices $265,195 8.49% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
2/26/2014 | SP | New Issue: UBS prices $200,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
2/25/2014 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
1/23/2014 | SP | New Issue: UBS prices $158,650 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
12/11/2013 | SP | New Issue: UBS prices $359,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
12/3/2013 | SP | New Issue: UBS prices $100,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
11/22/2013 | SP | New Issue: UBS prices $99,851 8.16% trigger yield optimization notes linked to Regeneron
|
11/5/2013 | SP | New Issue: UBS prices $113,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
10/29/2013 | SP | New Issue: UBS prices $99,789 11.75% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
10/28/2013 | SP | New Issue: UBS prices $294,819 11.96% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
10/28/2013 | SP | New Issue: UBS prices $99,687 8.65% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
10/22/2013 | SP | New Issue: JPMorgan prices $3.09 million 10.5% airbag autocallables linked to Regeneron
|
10/16/2013 | SP | JPMorgan to price 9%-11.25% airbag autocallables linked to Regeneron
|
10/16/2013 | SP | New Issue: UBS prices $129,790 11.23% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
10/11/2013 | SP | New Issue: UBS prices $171,100 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
9/11/2013 | SP | New Issue: UBS prices $345,000 airbag yield optimization notes linked to Regeneron Pharmaceuticals
|
8/27/2013 | SP | New Issue: UBS prices $608,209 9.58% trigger yield optimization notes linked to Regeneron Pharmaceuticals
|
8/15/2013 | SP | New Issue: UBS prices $100,000 airbag yield optimization notes linked to Regeneron Pharmaceuticals
|
8/15/2013 | SP | New Issue: UBS prices $165,000 trigger phoenix autocallable optimization securities linked to Regeneron Pharmaceuticals
|
7/16/2013 | SP | New Issue: Morgan Stanley prices $2.96 million 10.72% airbag autocallable notes linked to Regeneron
|
6/28/2013 | SP | New Issue: RBC prices $600,000 11.65% reverse convertibles linked to Regeneron Pharmaceuticals
|
5/6/2013 | CV | Market Commentary: Convertibles quiet; Regeneron slips; Auxilium, Chesapeake preferreds gain; Chiquita steady
|
5/3/2013 | CV | Market Commentary: Chemed expands on hedge on lawsuit news; TTM adds on hedge; Regeneron steady to lower
|
5/1/2013 | CV | Market Commentary: General Cable adds on hedge; Regeneron contracts amid stock surge; Ixia down; Cliffs eases
|
4/11/2013 | CV | Market Commentary: New RTI International bid higher in gray; existing RTI seen rich; Rite Aid mostly quiet
|
2/11/2013 | CV | Market Commentary: New Molina upsizes; planned Molina, Starwood bid higher in gray; Regeneron 'comes in'
|
11/20/2012 | CV | Market Commentary: Convertibles quiet ahead of Thanksgiving; high-grade names trade lightly; DryShips adds
|
4/26/2012 | CV | Market Commentary: Regeneron, Equinix jump outright, expand on hedge; Powerwave drops sharply; AMD trades above 103
|
3/20/2012 | CV | Market Commentary: Newmont trades actively in line; iStar Financial adds after buyback; Regeneron in on hedge
|
2/13/2012 | CV | Market Commentary: Regeneron jumps after boosting sales outlook; Beazer launches exchange; iStar unchanged
|
1/6/2012 | CV | Market Commentary: Convertibles start year strong; Regeneron jumps to 104; Dendreon gains; RF Micro drops
|
12/30/2011 | CV | Outlook 2012: Convertibles primary market set for weakness without higher rates, stronger economy
|
12/30/2011 | CV | Outlook 2012: MF Global's two convertibles deals: A 'black eye' for the market
|
11/14/2011 | CV | Market Commentary: Central European Distribution, Savient extend losses; Newer Human Genome premium rises
|
11/10/2011 | CV | Market Commentary: Take-Two's planned $200 million deal in focus ahead of pricing; Regeneron trades at 92.75
|
11/2/2011 | CV | Market Commentary: Human Genome's new $430 million deal prices at 99, edges higher; MF Global adds a little
|
10/21/2011 | CV | Market Commentary: SanDisk moves up on positive earnings; Old Nuance opens up; Investment-grade names active
|
10/19/2011 | CV | Market Commentary: Nuance Communications brings new deal, paper cracks par; Regeneron's new convertibles flat
|
10/18/2011 | CV | New Issue: Regeneron sells $400 million five-year convertible senior notes at 1.875%, up 30%
|
10/18/2011 | CV | Market Commentary: Regeneron prices $400 million notes; Nuance offers $600 million; Iconix, CompuCredit move
|
10/17/2011 | CV | Regeneron to sell up to $400 million five-year convertible notes
|
10/6/2010 | CVHYPF | Regeneron files automatic shelf covering stock, debt and preferreds
|
7/23/2009 | SS | Market Commentary: Bristol-Myers' buy narrows drug field; Noven tender opens; TransAlta offer considered risky
|
6/4/2008 | CV | Regeneron buys back $50 million convertibles
|
11/29/2007 | PP | New Issue: Regeneron will raise $312 million in private placement of stock
|
11/13/2006 | BT | Regeneron plans follow-on sale of 7.6 million shares via Morgan Stanley
|
11/8/2006 | BT | Merrill rates Regeneron neutral
|
11/6/2006 | BT | Regeneron reiterated at outperform by RBC
|
11/6/2006 | BT | Regeneron's quarterly net loss improves to $27.4 million from year ago
|
10/31/2006 | BT | Regeneron still outperform by RBC
|
10/31/2006 | BT | Merrill keeps Regeneron at neutral
|
10/19/2006 | BT | Regeneron reiterated at outperform by RBC
|
10/19/2006 | BT | Merrill keeps Regeneron at neutral
|
10/2/2006 | BT | RBC keeps Regeneron at outperform
|
9/7/2006 | BT | RBC rates Regeneron at outperform
|
9/7/2006 | BT | NIH selects Regeneron to produce genetically altered mice for research
|
8/3/2006 | BT | Merrill rates Regeneron neutral
|
8/3/2006 | BT | Regeneron reports second-quarter loss of $23.6 million, revenue up to $19.3 million
|
8/3/2006 | BT | RBC reiterates Regeneron outperform
|
7/27/2006 | BT | RBC begins coverage of Regeneron with outperform rating
|
6/9/2006 | BT | Regeneron says expansions, collaborations possible in VEGF Trap eye disease program
|
5/31/2006 | BT | Regeneron gets fast-track status for IL-1 Trap
|
5/4/2006 | BT | Regeneron stays at neutral by Merrill
|
5/3/2006 | BT | Regeneron reports 1Q net loss of $0.36 per share, revenues up to $18.2 million
|
5/3/2006 | BT | Market Commentary: MGI, SuperGen get nod from FDA for Dacogen; Impax stock climbs on FDA OK of generic Colestid
|
5/1/2006 | BT | Regeneron's phase 1 study of VEGF in wet AMD meets primary endpoints of safety, tolerability
|
4/19/2006 | BT | Regeneron stays at neutral by Merrill
|
4/19/2006 | BT | Regeneron completes trial enrollment for autoinflammatory disease treatment
|
3/7/2006 | BT | Regeneron at neutral by Merrill
|
2/27/2006 | BT | Regeneron kept at neutral by Merrill
|
2/24/2006 | BT | Regeneron reports $29.7 million 4Q net loss, predicts first regulatory submission in 2007/2008
|
2/2/2006 | BT | Regeneron's VEGF Trap demonstrates positive preliminary results for macular degeneration
|
2/1/2006 | BT | Regeneron at neutral by Merrill
|
1/31/2006 | BT | Regeneron, sanofi-aventis start phase 2 trial on VEGF Trap
|
12/22/2005 | BT | Regeneron expands VEGF pact with Aventis to include Japan
|
12/22/2005 | BT | Market Commentary: AtheroGenics zooms on $1 billion pact with AstraZeneca; Regeneron rises 6%; BioCryst bounces 16%
|
10/4/2005 | BT | Merrill Lynch keeps Regeneron at neutral
|
1/12/2005 | CV | Market Commentary: Level 3 higher on job cuts; CenturyTel off; Kodak up; Advanced Micro rebounds
|
12/14/2004 | CV | Regeneron files $200 million shelf, repaying 51/2% convertibles among possible aims
|
3/31/2003 | CV | Market Commentary: Market tiptoes into earnings season with anxiety, weighed down by uncertainty of war length
|
10/12/2001 | CV | New Issue: Regeneron $200 mln convertibles sold at 5.5% yield, up 12%
|